Drugs / PSB205
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03986606 | Jul 2019 → Feb 2021 | cancer | Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-04-10 | Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | Sound Biologics Announces FDA Allowance of its IND Application for PSB205, an Anti-PD-1/CTLA-4 MabPair, in Relapsed and Refractory Solid Tumors soundbiologics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PSB205 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03986606 ↗ |
| Route | Intravenous | “via IV infusion” NCT03986606 ↗ |